We are international
Donate
TEXT SIZE   


International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Owen - Minimal residual disease (MRD) assessment using multiparameter flow cytometry (MFC) predicts outcome in both intensively and non-intensively treated patients: results from the MRC myeloma IX trial
Roger G. Owen, MD
Leeds Cancer Centre
St. James's University Hospital
Leeds, UK
May 3-6, 2011
Paris, France
05.06.11
 related articles